Graduated in Biochemistry from the University of Castilla-La Mancha (2022). She carried out her Bachelors Thesis in the Dept. of Physical Chemistry, where she developed a bioinformatics project on the interactions between s-resistin and the transcription factors p53 and STAT3 using docking and molecular dynamics, with the aim of designing potential antibodies against this isoform.
Subsequently, she completed the Masters Degree in Pharmaceutical and Biotechnological Industry at the European University of Madrid and worked as a Quality Assurance Technician at Astellas Pharma (20232024), gaining experience in the regulatory field of the pharmaceutical industry and providing support to the Pharmacovigilance Dept.
With the aim of deepening her knowledge of the scientific basis of drug development, she later completed the Masters Degree in Pharmacological Research at the Autonomous University of Madrid (20242025). During this period, she developed her Masters Thesis focused on the metabolic reprogramming of tumor cells mediated by hypoxia-inducible factors (HIFs) .
After focusing her research on the molecular mechanisms involved in tumor progression and the identification of new therapeutic targets in oncology, she has currently joined the Chemical and Environmental Engineering Group (GIQA) as a predoctoral researcher. In this group, she will carry out her PhD thesis on the design of porous nanoparticles for the treatment of colorectal cancer.
Subsequently, she completed the Masters Degree in Pharmaceutical and Biotechnological Industry at the European University of Madrid and worked as a Quality Assurance Technician at Astellas Pharma (20232024), gaining experience in the regulatory field of the pharmaceutical industry and providing support to the Pharmacovigilance Dept.
With the aim of deepening her knowledge of the scientific basis of drug development, she later completed the Masters Degree in Pharmacological Research at the Autonomous University of Madrid (20242025). During this period, she developed her Masters Thesis focused on the metabolic reprogramming of tumor cells mediated by hypoxia-inducible factors (HIFs) .
After focusing her research on the molecular mechanisms involved in tumor progression and the identification of new therapeutic targets in oncology, she has currently joined the Chemical and Environmental Engineering Group (GIQA) as a predoctoral researcher. In this group, she will carry out her PhD thesis on the design of porous nanoparticles for the treatment of colorectal cancer.